The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Erythropoietin (EPO) Drugs-Global Market Insights and Sales Trends 2024
Synopsis
The global Erythropoietin (EPO) Drugs market size is expected to reach US$ 12990 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Erythropoietin (EPO) Drugs in various end use industries. The expanding demands from the Anemia, Kidney Disorders and Other,, are propelling Erythropoietin (EPO) Drugs market. Epoetin-alfa, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Darbepoetin-alfa segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Erythropoietin (EPO) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Erythropoietin (EPO) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Erythropoietin (EPO) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Erythropoietin (EPO) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Erythropoietin (EPO) Drugs covered in this report include Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon and LG Life Sciences, etc.
The global Erythropoietin (EPO) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Global Erythropoietin (EPO) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Erythropoietin (EPO) Drugs market, Segment by Type:
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Global Erythropoietin (EPO) Drugs market, by Application
Anemia
Kidney Disorders
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Erythropoietin (EPO) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Erythropoietin (EPO) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Erythropoietin (EPO) Drugs market size is expected to reach US$ 12990 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Erythropoietin (EPO) Drugs in various end use industries. The expanding demands from the Anemia, Kidney Disorders and Other,, are propelling Erythropoietin (EPO) Drugs market. Epoetin-alfa, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Darbepoetin-alfa segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Erythropoietin (EPO) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Erythropoietin (EPO) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Erythropoietin (EPO) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Erythropoietin (EPO) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Erythropoietin (EPO) Drugs covered in this report include Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon and LG Life Sciences, etc.
The global Erythropoietin (EPO) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Global Erythropoietin (EPO) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Erythropoietin (EPO) Drugs market, Segment by Type:
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Global Erythropoietin (EPO) Drugs market, by Application
Anemia
Kidney Disorders
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Erythropoietin (EPO) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Erythropoietin (EPO) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Erythropoietin (EPO) Drugs Market Overview
1.1 Erythropoietin (EPO) Drugs Product Overview
1.2 Erythropoietin (EPO) Drugs Market Segment by Type
1.2.1 Epoetin-alfa
1.2.2 Darbepoetin-alfa
1.2.3 Epoetin-beta
1.2.4 Others
1.3 Global Erythropoietin (EPO) Drugs Market Size by Type
1.3.1 Global Erythropoietin (EPO) Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Erythropoietin (EPO) Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Erythropoietin (EPO) Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Erythropoietin (EPO) Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Erythropoietin (EPO) Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Erythropoietin (EPO) Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Erythropoietin (EPO) Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Erythropoietin (EPO) Drugs Sales Breakdown by Type (2018-2023)
2 Global Erythropoietin (EPO) Drugs Market Competition by Company
2.1 Global Top Players by Erythropoietin (EPO) Drugs Sales (2018-2023)
2.2 Global Top Players by Erythropoietin (EPO) Drugs Revenue (2018-2023)
2.3 Global Top Players by Erythropoietin (EPO) Drugs Price (2018-2023)
2.4 Global Top Manufacturers Erythropoietin (EPO) Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Erythropoietin (EPO) Drugs Market Competitive Situation and Trends
2.5.1 Erythropoietin (EPO) Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Erythropoietin (EPO) Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Erythropoietin (EPO) Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Erythropoietin (EPO) Drugs Market
2.8 Key Manufacturers Erythropoietin (EPO) Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Erythropoietin (EPO) Drugs Status and Outlook by Region
3.1 Global Erythropoietin (EPO) Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Erythropoietin (EPO) Drugs Historic Market Size by Region
3.2.1 Global Erythropoietin (EPO) Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Erythropoietin (EPO) Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Erythropoietin (EPO) Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Erythropoietin (EPO) Drugs Forecasted Market Size by Region
3.3.1 Global Erythropoietin (EPO) Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Erythropoietin (EPO) Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Erythropoietin (EPO) Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Erythropoietin (EPO) Drugs by Application
4.1 Erythropoietin (EPO) Drugs Market Segment by Application
4.1.1 Anemia
4.1.2 Kidney Disorders
4.1.3 Other
4.2 Global Erythropoietin (EPO) Drugs Market Size by Application
4.2.1 Global Erythropoietin (EPO) Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Erythropoietin (EPO) Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Erythropoietin (EPO) Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Erythropoietin (EPO) Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Erythropoietin (EPO) Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Erythropoietin (EPO) Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Erythropoietin (EPO) Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Erythropoietin (EPO) Drugs Sales Breakdown by Application (2018-2023)
5 North America Erythropoietin (EPO) Drugs by Country
5.1 North America Erythropoietin (EPO) Drugs Historic Market Size by Country
5.1.1 North America Erythropoietin (EPO) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Erythropoietin (EPO) Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Erythropoietin (EPO) Drugs Sales in Value by Country (2018-2023)
5.2 North America Erythropoietin (EPO) Drugs Forecasted Market Size by Country
5.2.1 North America Erythropoietin (EPO) Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Erythropoietin (EPO) Drugs Sales in Value by Country (2024-2029)
6 Europe Erythropoietin (EPO) Drugs by Country
6.1 Europe Erythropoietin (EPO) Drugs Historic Market Size by Country
6.1.1 Europe Erythropoietin (EPO) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Erythropoietin (EPO) Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Erythropoietin (EPO) Drugs Sales in Value by Country (2018-2023)
6.2 Europe Erythropoietin (EPO) Drugs Forecasted Market Size by Country
6.2.1 Europe Erythropoietin (EPO) Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Erythropoietin (EPO) Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Erythropoietin (EPO) Drugs by Region
7.1 Asia-Pacific Erythropoietin (EPO) Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Erythropoietin (EPO) Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Erythropoietin (EPO) Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Erythropoietin (EPO) Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Erythropoietin (EPO) Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Erythropoietin (EPO) Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Erythropoietin (EPO) Drugs Sales in Value by Region (2024-2029)
8 Latin America Erythropoietin (EPO) Drugs by Country
8.1 Latin America Erythropoietin (EPO) Drugs Historic Market Size by Country
8.1.1 Latin America Erythropoietin (EPO) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Erythropoietin (EPO) Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Erythropoietin (EPO) Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Erythropoietin (EPO) Drugs Forecasted Market Size by Country
8.2.1 Latin America Erythropoietin (EPO) Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Erythropoietin (EPO) Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Erythropoietin (EPO) Drugs by Country
9.1 Middle East and Africa Erythropoietin (EPO) Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Erythropoietin (EPO) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Erythropoietin (EPO) Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Erythropoietin (EPO) Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Erythropoietin (EPO) Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Erythropoietin (EPO) Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Erythropoietin (EPO) Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Amgen
10.1.1 Amgen Company Information
10.1.2 Amgen Introduction and Business Overview
10.1.3 Amgen Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Amgen Erythropoietin (EPO) Drugs Products Offered
10.1.5 Amgen Recent Development
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information
10.2.2 Johnson & Johnson Introduction and Business Overview
10.2.3 Johnson & Johnson Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Johnson & Johnson Erythropoietin (EPO) Drugs Products Offered
10.2.5 Johnson & Johnson Recent Development
10.3 Roche
10.3.1 Roche Company Information
10.3.2 Roche Introduction and Business Overview
10.3.3 Roche Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Roche Erythropoietin (EPO) Drugs Products Offered
10.3.5 Roche Recent Development
10.4 Galenica
10.4.1 Galenica Company Information
10.4.2 Galenica Introduction and Business Overview
10.4.3 Galenica Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Galenica Erythropoietin (EPO) Drugs Products Offered
10.4.5 Galenica Recent Development
10.5 Emcure
10.5.1 Emcure Company Information
10.5.2 Emcure Introduction and Business Overview
10.5.3 Emcure Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Emcure Erythropoietin (EPO) Drugs Products Offered
10.5.5 Emcure Recent Development
10.6 Kyowa Hakko Kirin
10.6.1 Kyowa Hakko Kirin Company Information
10.6.2 Kyowa Hakko Kirin Introduction and Business Overview
10.6.3 Kyowa Hakko Kirin Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Kyowa Hakko Kirin Erythropoietin (EPO) Drugs Products Offered
10.6.5 Kyowa Hakko Kirin Recent Development
10.7 3SBio
10.7.1 3SBio Company Information
10.7.2 3SBio Introduction and Business Overview
10.7.3 3SBio Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 3SBio Erythropoietin (EPO) Drugs Products Offered
10.7.5 3SBio Recent Development
10.8 Biocon
10.8.1 Biocon Company Information
10.8.2 Biocon Introduction and Business Overview
10.8.3 Biocon Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Biocon Erythropoietin (EPO) Drugs Products Offered
10.8.5 Biocon Recent Development
10.9 LG Life Sciences
10.9.1 LG Life Sciences Company Information
10.9.2 LG Life Sciences Introduction and Business Overview
10.9.3 LG Life Sciences Erythropoietin (EPO) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 LG Life Sciences Erythropoietin (EPO) Drugs Products Offered
10.9.5 LG Life Sciences Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Erythropoietin (EPO) Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Erythropoietin (EPO) Drugs Industrial Chain Analysis
11.4 Erythropoietin (EPO) Drugs Market Dynamics
11.4.1 Erythropoietin (EPO) Drugs Industry Trends
11.4.2 Erythropoietin (EPO) Drugs Market Drivers
11.4.3 Erythropoietin (EPO) Drugs Market Challenges
11.4.4 Erythropoietin (EPO) Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Erythropoietin (EPO) Drugs Distributors
12.3 Erythropoietin (EPO) Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
